Evidence map›Paper›PMID 39911713›Full record

ArticleFrontiers in microbiology2024

Comprehensive genomic surveillance reveals transmission profiles of extensively drug-resistant tuberculosis cases in Pará, Brazil.

Davi Josué Marcon, Abhinav Sharma, Alex Brito Souza, Rafaella Bonfim Barros, Valnete das Graças Dantas Andrade, Ricardo José de Paula Souza Guimarães, Luana Nepomuceno Gondim Lima, Lúcia Helena Martins Tavares Monteiro, Ana Judith Pires Garcia Quaresma, Layana Rufino Ribeiro and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Open-access genomic drug resistance prediction tools forJournal of clinical microbiology · 2026
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Davi Josué Marcon *Programa de Pós-Graduação em Biologia Parasitária na Amazônia, Belém, Brazil.
Abhinav Sharma *South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Alex Brito SouzaPrograma de Pós-Graduação em Biologia Parasitária na Amazônia, Belém, Brazil.
Rafaella Bonfim BarrosLaboratório Central do Estado do Pará, Belém, Pará, Brazil.
Valnete das Graças Dantas AndradeLaboratório Central do Estado do Pará, Belém, Pará, Brazil.
Ricardo José de Paula Souza GuimarãesSeção de Epidemiologia do Instituto Evandro Chagas, Ananindeua, Pará, Brazil.
Luana Nepomuceno Gondim LimaPrograma de Pós-Graduação em Biologia Parasitária na Amazônia, Belém, Brazil.
Lúcia Helena Martins Tavares MonteiroSecretaria de Estado da Saúde do Pará, Belém, Pará, Brazil.
Ana Judith Pires Garcia QuaresmaPrograma de Pós-Graduação em Biologia Parasitária na Amazônia, Belém, Brazil.
Layana Rufino RibeiroSeção de Bacteriologia do Instituto Evandro Chagas, Ananindeua, Pará, Brazil.
Philip Noel SuffysLaboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Robin Mark WarrenSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Carlos Augusto Abreu Alberio *Hospital Universitário João de Barros Barreto, Ambulatório de Tuberculose Multiressistente, Universidade Federal do Pará, Belém, Pará, Brazil.
Karla Valéria Batista Lima *Programa de Pós-Graduação em Biologia Parasitária na Amazônia, Belém, Brazil.
Emilyn Costa Conceição *South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bedaquiline, an antimicrobial used to treat drug-resistant tuberculosis (DR-TB), was introduced in Brazil in October 2021. Monitoring the emergence and transmission of DR-TB is crucial for implementing public health to control the spread of DR strains of

Indexed as

bedaquilinedrug-resistant tuberculosisextensively drug-resistant tuberculosisgenomic surveillancewhole-genome sequencing

Identifiers

PMID39911713
PMCPMC11794272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.